Investors
UNICYTE’s current 100% shareholder is prepared to offer a small group of financial investors the opportunity to participate in the company’s significant growth.
New investors
FMC seeks a group of competent financial partners to act as sparring partners in the further development of this important asset
FMC is prepared to forego rights outside of its core kidney indication area to maximize the overall value of Unicyte.
Investment is structured as bridge to an IPO as early as 2024/2025
Our edge
UCD/HCC/CKD:
- No other competitor in targeted patient segments
- Superior safety profile
- Disease modifying & curative treatment
- Extensive pre-clinical data
Manufacturing:
- Highly expandable cells: 30 passages without change in growth kinetics or genetic stability
- GMP platforms and potency assays fully established
- Stronger manufacturing robustness
Intellectual Property:
- Unlike MSCs and iPSCs, fully patent protected cell line as a starting material; also the fact that the IP Department of FMC supported the project from the early days until today
Overall:
- Broadest experience in developing EV-based assets with globally leading team
- Proprietary products, fully patent-protected in both cell therapy and nano-Extracellular Vesicles field
Islets:
- Entire islets, not just beta-cells
- No tumorigenicity seen with proprietary stem cells (HLSCs) used as starting material for islet formation
- Efficient manufacturing process
Globally leading team
Management
- Former Managing Director of Fresenius Medical Care Ventures
- Former Partner at Catenion
- >20 years of experience in life science industries
- Former Head of Medical at InterMune Inc.
- Former Head of R&D Merck KGaA
- Former Head of Manufacturing and COO in various biotech and big pharma companies
- Manufacturing expert in Cell & Gene Therapy, 20 years of experience
- Former Senior Manager at Catenion
- 20 years experience in the life sciences
Prof. Giovanni Camussi - Head of Research
- World-leading scientist in stem cells & nEVs with >550 publications
- Professor Emeritus at the University of Torino
- QP of University of Torino’s translational medicine Cell Factory
- Inventor on four patents, and author on a substantial number of publications
- Associate professor at University of Torinio
- Widely published, with more than 10k citations in the fields around stem cell induced tissue regeneration by EVs
- Leading researcher on human liver stem cells
- Inventor on 5 patents
Board of Directors
- Former Managing Director of Fresenius Medical Care Ventures
- Former Partner at Catenion
- >20 years of experience in life science industries
- Executive Vice President and Global General Counsel for Fresenius Medical Care
- CEO Critical Care at Fresenius Medical Care
- Managing Director at Fresenius AG
Advisors
Prof. Paul Robbins
- Prof. of Biochemistry, Molecular Biology and Biophysics at University of Minnesota
- Former Professor Molecular Medicine, Metabolism and Aging at Scripps Research Institute
- Co-founder of 2 biotech companies
- Head of Diabetes Research Institute and Cell Transplant Center at University of Miami, FL, USA
- Leading scientist in the field of clinical islet transplantation
- Appointed by the Italian Minister of Health to Italy’s Supreme Council of Health
- Former President of Group Research and Corp. Exec. Committee member at Roche
- Former Board member Genentech & Chugai, former Chairman of Immonocore Ltd. and Adaptimmune Ltd
- Non-executive member of a number of Biotech company boards
Our partners
We are open to a wide variety of collaborations and partnerships along and within our entire value chain – research, manufacturing and development through to commercialisation. We have an indirect cost rate capped at 30% of direct costs for all of our industry-sponsored research grants to universities. If you would like to know more, please contact us at collaboration@unicyte.ch.
Achievements timeline
Unicyte was founded integrating scientific excellence and entrepreneurial Leadership
Achievements timeline
Unicyte was founded integrating scientific excellence and entrepreneurial Leadership
